Kerry Group has established a new biotechnology centre in Leipzig, Germany.
This centre will focus on the development of innovative biotech solutions across food, beverage, and pharma applications.
Kerry, which is a global leader in taste and nutrition, says it has significantly developed its biotechnology capabilities in recent years, having built a dedicated technology and manufacturing footprint through a combination of strategic acquisitions and organic investment.
It says the Biotechnology Centre in Leipzig will further enhance its global infrastructure in this space.
Kerry says it has chosen Leipzig as the location for this new facility because of what it says is the exceptional biotechnology skills base and research cluster that has developed in the city.
The primary activities that will be undertaken at the new facility will include enzyme and strain identification and engineering, fermentation and bioprocess development and scale-up, and production.
Marking the opening in Leipzig, Kerry CEO, Edmond Scanlon said biotechnology solutions present a new horizon of innovation and opportunity for global food, beverage and pharmaceutical markets.
He says Kerry’s existing portfolio of biotech capabilities, along with this new biotechnology centre, enables them to play a leading role in bringing the next generation of discoveries in this space to market, supporting their customers as they meet consumer needs for sustainable nutrition.
